Medical Oncology, Journal Year: 2024, Volume and Issue: 42(1)
Published: Dec. 12, 2024
Language: Английский
Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)
Published: Jan. 15, 2025
The last decade has witnessed unprecedented succusses with the use of immune checkpoint inhibitors in treating cancer. Nevertheless, proportion patients who respond favorably to treatment remained rather modest, partially due resistance. This fueled a wave research into potential mechanisms resistance which can be classified primary or acquired after an initial response. In current review, we summarize what is known so far about terms being tumor-intrinsic tumor-extrinsic taking account multimodal crosstalk between tumor, system compartment and other host-related factors.
Language: Английский
Citations
3
Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 16
Published: March 21, 2025
Immunotherapy has emerged as a preeminent force in the domain of cancer therapeutics and achieved remarkable breakthroughs. Nevertheless, high resistance become most substantial impediment restricting its clinical efficacy. Beta-2 microglobulin (B2M), light chain major histocompatibility complex (MHC) class I, plays an indispensable part by presenting tumor antigens to cytotoxic T lymphocytes (CTLs) for exerting anti-tumor effects. Accumulating evidence indicates that B2M mutation/defect is one key mechanisms underlying immunotherapy resistance. Therefore, elucidating role played devising effective strategies battle against are pressing issues. This review will systematically expound upon them, aiming provide insight into potential promising target anticancer immune response.
Language: Английский
Citations
2
Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)
Published: Dec. 26, 2024
Immune checkpoint inhibitors (ICIs) have dramatically transformed the treatment landscape for various malignancies, achieving notable clinical outcomes across a wide range of indications. Despite these advances, resistance to immune blockade (ICB) remains critical challenge, characterized by variable response rates and non-durable benefits. However, growing research into complex intrinsic extrinsic characteristics tumors has advanced our understanding mechanisms behind ICI resistance, potentially improving outcomes. Additionally, robust predictive biomarkers are crucial optimizing patient selection maximizing efficacy ICBs. Recent studies emphasized that multiple rational combination strategies can overcome enhance susceptibility ICIs. These findings not only deepen tumor biology but also reveal unique action sensitizing agents, extending benefits in cancer immunotherapy. In this review, we will explore underlying ICIs, discuss significance microenvironment (TIME) biomarkers, analyze current outline alternative effectiveness including personalized
Language: Английский
Citations
10
Cancer Cell, Journal Year: 2024, Volume and Issue: 42(12), P. 2032 - 2044.e6
Published: Nov. 7, 2024
Immune checkpoint blockade (ICB) triggers tumor ferroptosis. However, most patients are unresponsive to ICB. Tumors might evade ferroptosis in the microenvironment (TME). Here, we discover SLC13A3 is an itaconate transporter cells and endows resistance, diminishing immunity ICB efficacy. Mechanistically, uptake via from tumor-associated macrophages (TAMs), thereby activating NRF2-SLC7A11 pathway escaping immune-mediated Structural modeling molecular docking analysis identify a functional inhibitor for (SLC13A3i). Deletion of ACOD1 (an essential enzyme synthesis) macrophages, genetic ablation tumors, or treatment with SLC13A3i sensitize tumors ferroptosis, curb progression, bolster effectiveness. Thus, interplay between TAMs SLC13A3-itaconate-NRF2-SLC7A11 axis as previously unknown immune resistant mechanism TME promising immunometabolic target treating
Language: Английский
Citations
9
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217616 - 217616
Published: March 1, 2025
Language: Английский
Citations
1
Clinical and Translational Medicine, Journal Year: 2024, Volume and Issue: 14(9)
Published: Sept. 1, 2024
Language: Английский
Citations
4
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 380, P. 860 - 874
Published: Feb. 19, 2025
Language: Английский
Citations
0
Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0
Published: Jan. 1, 2025
Nanozymes, which are nanomaterials that replicate the catalytic activities of natural enzymes in biological systems, have recently demonstrated considerable potential improving cancer immunotherapy by altering tumor microenvironment. Nanozyme-driven immune responses represent an innovative therapeutic modality with high effectiveness and minimal side effects. These nanozymes activate system to specifically recognize destroy cells. Combined immunotherapeutic agents, can amplify anti-cancer integrating remodeling immunogenic cell death (ICD). This review offers a thorough discussion about various involved immunity, including those mimicking catalase (CAT), superoxide dismutase (SOD), peroxidase (POD), oxidase (OXD). It also discusses challenges future directions for translating nanozyme platforms into clinical applications, enhancing susceptibility cells immunotherapy. Nanozyme-based strategies substantial oncology, offering new effective options management.
Language: Английский
Citations
0
Translational Oncology, Journal Year: 2025, Volume and Issue: 54, P. 102353 - 102353
Published: March 8, 2025
Language: Английский
Citations
0
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: 1880(3), P. 189298 - 189298
Published: March 13, 2025
Language: Английский
Citations
0